Latest Non Dilutive Funding News

AdAlta Limited has launched its 'East to West' cellular immunotherapy operations through a strategic collaboration with Shanghai Cell Therapy Group to co-develop BZDS1901, an innovative CAR-T therapy targeting mesothelioma and other solid cancers. The company also strengthened its balance sheet by raising $2.8 million via private placements and repaying key investment agreements.

Critical Resources Limited has significantly expanded its Mavis Lake Lithium Project in Ontario and progressed gold exploration in New Zealand, while securing exclusive rights to evaluate cutting-edge solid-state battery technology.

Latitude 66 Ltd has strengthened its cash position through strategic asset sales and repaying a short-term loan, positioning itself for targeted exploration in Finland and Western Australia.

Neurizon Therapeutics has locked in a $6 million cash rebate from the Australian Government’s R&D Tax Incentive, underpinning its upcoming HEALEY ALS Platform Trial with first patient dosing slated for early 2026.

VBX Limited has announced significant enhancements to its Wuudagu Bauxite Project, increasing mining rates and securing $2 million in funding to support an expanded feasibility study.

Metallium Limited has kicked off commissioning at its Texas Technology Campus, sealed a multi-year feedstock deal with Glencore, and bolstered its balance sheet with a A$75 million capital raise, setting the stage for commercialisation in 2026.

GoldArc Resources has identified multiple high-priority gold targets at its Leonora projects and secured strategic partnerships to accelerate mining development, backed by a $2.5 million cash advance facility.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Cosmo Metals has identified two promising volcanic massive sulphide targets within the Mt Everest – Mona corridor at its Bingara Project, setting the stage for the first drilling campaign in this historically underexplored VMS belt.

EMVision Medical Devices reports strong clinical trial progress for its portable brain scanners, backed by solid cash reserves and milestone grant funding.